In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes

Emmanuel Contassot, William J Murphy, Régis Angonin, Jean Jacques Pavy, Marcelo C. Bittencourt, Éric Robinet, Craig W. Reynolds, Jean Yves Cahn, Patrick Hervé, Pierre Tiberghien

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Background. We are presently investigating the therapeutic potential of herpes simplex-thymidine kinase-expressing donor T cells in the setting of a T cell-depleted allogeneic bone marrow transplantation. The generation, expansion, and selection of the gene-modified T cells require a 12-day ex vivo culture period in high-dose interleukin (IL)-2 that could significantly alter their in vivo alloreactivity. Methods. We evaluated the alloreactive potential of such cultured cells in a murine allogeneic bone marrow transplantation model. Results. The present studies demonstrate that ex vivo- expanded cultured T cells are capable of strong alloreactivity as evidenced by the occurrence of lethal acute graft-versus-host disease (GVHD). However, GVHD mortality after administration of the cultured T cells occurred later than after the administration of a same number of fresh T cells. Similar kinetics of GVHD-induced mortality between cultured and fresh T cells required a 10-fold increase in the number of cultured T cells, indicating a reduced alloreactive potential of these cells. The addition of a 2-day 'resting' period in low-dose IL-2 resulted in T cells with enhanced alloreactive potential identical to the alloreactivity observed with fresh T cells. Conclusion. Ex vivo IL-2 expanded T cells are capable of significant in vivo alloreactivity. However, an increase in the number of cultured T cells administered or the introduction of a short resting culture period prior to infusion is necessary in order to achieve in vivo alloreactivity identical to the alloreactivity observed with fresh T cells.

Original languageEnglish (US)
Pages (from-to)1365-1370
Number of pages6
JournalTransplantation
Volume65
Issue number10
DOIs
StatePublished - May 27 1998
Externally publishedYes

Fingerprint

T-Lymphocytes
Cultured Cells
Graft vs Host Disease
Interleukin-2
Homologous Transplantation
Bone Marrow Transplantation
Herpes Simplex
Thymidine Kinase
Mortality
Genes

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Contassot, E., Murphy, W. J., Angonin, R., Pavy, J. J., Bittencourt, M. C., Robinet, É., ... Tiberghien, P. (1998). In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. Transplantation, 65(10), 1365-1370. https://doi.org/10.1097/00007890-199805270-00014

In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. / Contassot, Emmanuel; Murphy, William J; Angonin, Régis; Pavy, Jean Jacques; Bittencourt, Marcelo C.; Robinet, Éric; Reynolds, Craig W.; Cahn, Jean Yves; Hervé, Patrick; Tiberghien, Pierre.

In: Transplantation, Vol. 65, No. 10, 27.05.1998, p. 1365-1370.

Research output: Contribution to journalArticle

Contassot, E, Murphy, WJ, Angonin, R, Pavy, JJ, Bittencourt, MC, Robinet, É, Reynolds, CW, Cahn, JY, Hervé, P & Tiberghien, P 1998, 'In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes', Transplantation, vol. 65, no. 10, pp. 1365-1370. https://doi.org/10.1097/00007890-199805270-00014
Contassot E, Murphy WJ, Angonin R, Pavy JJ, Bittencourt MC, Robinet É et al. In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. Transplantation. 1998 May 27;65(10):1365-1370. https://doi.org/10.1097/00007890-199805270-00014
Contassot, Emmanuel ; Murphy, William J ; Angonin, Régis ; Pavy, Jean Jacques ; Bittencourt, Marcelo C. ; Robinet, Éric ; Reynolds, Craig W. ; Cahn, Jean Yves ; Hervé, Patrick ; Tiberghien, Pierre. / In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes. In: Transplantation. 1998 ; Vol. 65, No. 10. pp. 1365-1370.
@article{0c0fe350cc554854b6eafc7c8aee7283,
title = "In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes",
abstract = "Background. We are presently investigating the therapeutic potential of herpes simplex-thymidine kinase-expressing donor T cells in the setting of a T cell-depleted allogeneic bone marrow transplantation. The generation, expansion, and selection of the gene-modified T cells require a 12-day ex vivo culture period in high-dose interleukin (IL)-2 that could significantly alter their in vivo alloreactivity. Methods. We evaluated the alloreactive potential of such cultured cells in a murine allogeneic bone marrow transplantation model. Results. The present studies demonstrate that ex vivo- expanded cultured T cells are capable of strong alloreactivity as evidenced by the occurrence of lethal acute graft-versus-host disease (GVHD). However, GVHD mortality after administration of the cultured T cells occurred later than after the administration of a same number of fresh T cells. Similar kinetics of GVHD-induced mortality between cultured and fresh T cells required a 10-fold increase in the number of cultured T cells, indicating a reduced alloreactive potential of these cells. The addition of a 2-day 'resting' period in low-dose IL-2 resulted in T cells with enhanced alloreactive potential identical to the alloreactivity observed with fresh T cells. Conclusion. Ex vivo IL-2 expanded T cells are capable of significant in vivo alloreactivity. However, an increase in the number of cultured T cells administered or the introduction of a short resting culture period prior to infusion is necessary in order to achieve in vivo alloreactivity identical to the alloreactivity observed with fresh T cells.",
author = "Emmanuel Contassot and Murphy, {William J} and R{\'e}gis Angonin and Pavy, {Jean Jacques} and Bittencourt, {Marcelo C.} and {\'E}ric Robinet and Reynolds, {Craig W.} and Cahn, {Jean Yves} and Patrick Herv{\'e} and Pierre Tiberghien",
year = "1998",
month = "5",
day = "27",
doi = "10.1097/00007890-199805270-00014",
language = "English (US)",
volume = "65",
pages = "1365--1370",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "10",

}

TY - JOUR

T1 - In vivo alloreactive potential of ex vivo-expanded primary T lymphocytes

AU - Contassot, Emmanuel

AU - Murphy, William J

AU - Angonin, Régis

AU - Pavy, Jean Jacques

AU - Bittencourt, Marcelo C.

AU - Robinet, Éric

AU - Reynolds, Craig W.

AU - Cahn, Jean Yves

AU - Hervé, Patrick

AU - Tiberghien, Pierre

PY - 1998/5/27

Y1 - 1998/5/27

N2 - Background. We are presently investigating the therapeutic potential of herpes simplex-thymidine kinase-expressing donor T cells in the setting of a T cell-depleted allogeneic bone marrow transplantation. The generation, expansion, and selection of the gene-modified T cells require a 12-day ex vivo culture period in high-dose interleukin (IL)-2 that could significantly alter their in vivo alloreactivity. Methods. We evaluated the alloreactive potential of such cultured cells in a murine allogeneic bone marrow transplantation model. Results. The present studies demonstrate that ex vivo- expanded cultured T cells are capable of strong alloreactivity as evidenced by the occurrence of lethal acute graft-versus-host disease (GVHD). However, GVHD mortality after administration of the cultured T cells occurred later than after the administration of a same number of fresh T cells. Similar kinetics of GVHD-induced mortality between cultured and fresh T cells required a 10-fold increase in the number of cultured T cells, indicating a reduced alloreactive potential of these cells. The addition of a 2-day 'resting' period in low-dose IL-2 resulted in T cells with enhanced alloreactive potential identical to the alloreactivity observed with fresh T cells. Conclusion. Ex vivo IL-2 expanded T cells are capable of significant in vivo alloreactivity. However, an increase in the number of cultured T cells administered or the introduction of a short resting culture period prior to infusion is necessary in order to achieve in vivo alloreactivity identical to the alloreactivity observed with fresh T cells.

AB - Background. We are presently investigating the therapeutic potential of herpes simplex-thymidine kinase-expressing donor T cells in the setting of a T cell-depleted allogeneic bone marrow transplantation. The generation, expansion, and selection of the gene-modified T cells require a 12-day ex vivo culture period in high-dose interleukin (IL)-2 that could significantly alter their in vivo alloreactivity. Methods. We evaluated the alloreactive potential of such cultured cells in a murine allogeneic bone marrow transplantation model. Results. The present studies demonstrate that ex vivo- expanded cultured T cells are capable of strong alloreactivity as evidenced by the occurrence of lethal acute graft-versus-host disease (GVHD). However, GVHD mortality after administration of the cultured T cells occurred later than after the administration of a same number of fresh T cells. Similar kinetics of GVHD-induced mortality between cultured and fresh T cells required a 10-fold increase in the number of cultured T cells, indicating a reduced alloreactive potential of these cells. The addition of a 2-day 'resting' period in low-dose IL-2 resulted in T cells with enhanced alloreactive potential identical to the alloreactivity observed with fresh T cells. Conclusion. Ex vivo IL-2 expanded T cells are capable of significant in vivo alloreactivity. However, an increase in the number of cultured T cells administered or the introduction of a short resting culture period prior to infusion is necessary in order to achieve in vivo alloreactivity identical to the alloreactivity observed with fresh T cells.

UR - http://www.scopus.com/inward/record.url?scp=0032571988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032571988&partnerID=8YFLogxK

U2 - 10.1097/00007890-199805270-00014

DO - 10.1097/00007890-199805270-00014

M3 - Article

C2 - 9625020

AN - SCOPUS:0032571988

VL - 65

SP - 1365

EP - 1370

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 10

ER -